HighTide Therapeutics

HighTide Therapeutics is an innovative biopharmaceutical company focused on cardiorenal metabolic (CKM) diseases and dedicated to developing multifunctional, multi-target therapies. Grounded in source innovation, the company is committed to developing breakthrough therapies that provide global patients with solutions offering both symptomatic relief and root-cause treatment, along with comprehensive clinical benefits. HighTide has established a global product pipeline with 100% independent intellectual property rights and has conducted clinical studies for multiple CKM indications across various countries and regions. The company’s core product, HTD1801, has received two Fast Track designations and one Orphan Drug designation from the U.S. Food and Drug Administration (FDA), and was included in the National Major Science and Technology Special Project for “Major New Drug Creation” during China’s 13th Five-Year Plan period.